| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 0/6 |
Lucira Health, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$0.0001 |
| 52 Week Hoogtepunt | US$1.45 |
| 52 Week Laag | US$0.000001 |
| Bèta | 2.39 |
| 11 maand verandering | -50.00% |
| 3 maanden verandering | -99.44% |
| 1 Jaar Verandering | -99.99% |
| 33 jaar verandering | n/a |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -100.00% |
Recent nieuws en updates
Recent updates
Lucira Health reports early data for point of care chlamydia and gonorrhea assays
Sep 29Lucira COVID & Flu test gets emergency use authorization from Health Canada
Aug 11Lucira Health Sees Strong Revenue Growth But Needs More Cash
Mar 10Analysts' Revenue Estimates For Lucira Health, Inc. (NASDAQ:LHDX) Are Surging Higher
Nov 25
Is Lucira Health (NASDAQ:LHDX) In A Good Position To Invest In Growth?
Jun 29Lucira Health appoints medtech veteran Kevin Collins as CRO
May 28Health Canada issues 'authorization with conditions' for Lucira's COVID-19 test kit
Apr 26Rendement voor aandeelhouders
| LHDX.Q | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 0% | 0.2% | -1.6% |
| 1Y | -100.0% | 25.8% | 30.8% |
Rendement versus industrie: LHDX.Q underperformed the US Medical Equipment industry which returned -1.8% over the past year.
Rendement versus markt: LHDX.Q underperformed the US Market which returned 15.2% over the past year.
Prijsvolatiliteit
| LHDX.Q volatility | |
|---|---|
| LHDX.Q Average Weekly Movement | 2,860.0% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: LHDX.Q's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: LHDX.Q's weekly volatility has increased from 1417% to 2860% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2013 | 221 | n/a | www.lucirahealth.com |
Lucira Health, Inc. Samenvatting
| LHDX.Q fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$4.18k |
| Inkomsten(TTM) | -US$143.28m |
| Inkomsten(TTM) | US$212.13m |
0.0x
P/S-verhouding0.0x
Koers/WinstverhoudingIs LHDX.Q overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| LHDX.Q resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$212.13m |
| Kosten van inkomsten | US$251.34m |
| Brutowinst | -US$39.20m |
| Overige uitgaven | US$104.07m |
| Inkomsten | -US$143.28m |
Laatst gerapporteerde inkomsten
Sep 30, 2022
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -3.43 |
| Brutomarge | -18.48% |
| Nettowinstmarge | -67.54% |
| Schuld/Eigen Vermogen Verhouding | 48.3% |
Hoe presteerde LHDX.Q op de lange termijn?
Bekijk historische prestaties en vergelijking